Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors
- PMID:17986216
- DOI: 10.1111/j.1471-4159.2007.05063.x
Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors
Abstract
Agonist-induced internalization of G protein-coupled receptors (GPCRs) is an important mechanism for regulating signaling transduction of functional receptors at the plasma membrane. We demonstrate here that both caveolae/lipid-rafts- and clathrin-coated-pits-mediated pathways were involved in agonist-induced endocytosis of the cannabinoid type 1 receptor (CB1R) in stably transfected human embryonic kidney (HEK) 293 cells and that the internalized receptors were predominantly sorted into recycling pathway for reactivation. The treatment of CB1 receptors with the low endocytotic agonist Delta9-THC induced a faster receptor desensitization and slower resensitization than the high endocytotic agonist WIN 55,212-2. In addition, the blockade of receptor endocytosis or recycling pathway markedly enhanced agonist-induced CB1 receptor desensitization. Furthermore, co-expression of phospholipase D2, an enhancer of receptor endocytosis, reduced CB1 receptor desensitization, whereas co-expression of a phospholipase D2 negative mutant significantly increased the desensitization after WIN 55,212-2 treatment. These findings provide evidences for the importance of receptor endocytosis in counteracting CB1 receptor desensitization by facilitating receptor reactivation. Moreover, in primary cultured neurons, the low endocytotic agonist Delta9-THC or anandamide exhibited a greater desensitization of endogenous CB1 receptors than the high endocytotic agonist WIN 55,212-2, CP 55940 or 2-arachidonoyl glycerol, indicating that cannabinoids with high endocytotic efficacy might cause reduced development of cannabinoid tolerance to some kind cannabinoid-mediated effects.
Similar articles
- Internalization and recycling of the CB1 cannabinoid receptor.Hsieh C, Brown S, Derleth C, Mackie K.Hsieh C, et al.J Neurochem. 1999 Aug;73(2):493-501. doi: 10.1046/j.1471-4159.1999.0730493.x.J Neurochem. 1999.PMID:10428044
- Differential β-arrestin2 requirements for constitutive and agonist-induced internalization of the CB1 cannabinoid receptor.Gyombolai P, Boros E, Hunyady L, Turu G.Gyombolai P, et al.Mol Cell Endocrinol. 2013 Jun 15;372(1-2):116-27. doi: 10.1016/j.mce.2013.03.013. Epub 2013 Mar 27.Mol Cell Endocrinol. 2013.PMID:23541635
- [The synthetic cannabinoid analog WIN 55,212-2 potentiates the amplitudes of glycine-activated currents].Iatsenko NM, Tsintsadze TSh, Lozova NO.Iatsenko NM, et al.Fiziol Zh (1994). 2007;53(3):31-7.Fiziol Zh (1994). 2007.PMID:17725041Ukrainian.
- Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.Ashton JC, Wright JL, McPartland JM, Tyndall JD.Ashton JC, et al.Curr Med Chem. 2008;15(14):1428-43. doi: 10.2174/092986708784567716.Curr Med Chem. 2008.PMID:18537620Review.
- [Drug discrimination properties and cytotoxicity of the cannabinoid receptor ligands].Tomiyama K, Funada M.Tomiyama K, et al.Nihon Arukoru Yakubutsu Igakkai Zasshi. 2012 Jun;47(3):135-43.Nihon Arukoru Yakubutsu Igakkai Zasshi. 2012.PMID:22894054Review.Japanese.
Cited by
- Highly Selective Drug-Derived Fluorescent Probes for the Cannabinoid Receptor Type 1 (CB1R).Mach L, Omran A, Bouma J, Radetzki S, Sykes DA, Guba W, Li X, Höffelmeyer C, Hentsch A, Gazzi T, Mostinski Y, Wasinska-Kalwa M, de Molnier F, van der Horst C, von Kries JP, Vendrell M, Hua T, Veprintsev DB, Heitman LH, Grether U, Nazare M.Mach L, et al.J Med Chem. 2024 Jul 25;67(14):11841-11867. doi: 10.1021/acs.jmedchem.4c00465. Epub 2024 Jul 11.J Med Chem. 2024.PMID:38990855Free PMC article.
- Cannabinoid receptor interacting protein suppresses agonist-driven CB1 receptor internalization and regulates receptor replenishment in an agonist-biased manner.Blume LC, Leone-Kabler S, Luessen DJ, Marrs GS, Lyons E, Bass CE, Chen R, Selley DE, Howlett AC.Blume LC, et al.J Neurochem. 2016 Nov;139(3):396-407. doi: 10.1111/jnc.13767. Epub 2016 Sep 26.J Neurochem. 2016.PMID:27513693Free PMC article.
- A NanoBiT assay to monitor membrane proteins trafficking for drug discovery and drug development.Reyes-Alcaraz A, Lucero Garcia-Rojas EY, Merlinsky EA, Seong JY, Bond RA, McConnell BK.Reyes-Alcaraz A, et al.Commun Biol. 2022 Mar 8;5(1):212. doi: 10.1038/s42003-022-03163-9.Commun Biol. 2022.PMID:35260793Free PMC article.
- Dynamic Change of Endocannabinoid Signaling in the Medial Prefrontal Cortex Controls the Development of Depression After Neuropathic Pain.Mecca CM, Chao D, Yu G, Feng Y, Segel I, Zhang Z, Rodriguez-Garcia DM, Pawela CP, Hillard CJ, Hogan QH, Pan B.Mecca CM, et al.J Neurosci. 2021 Sep 1;41(35):7492-7508. doi: 10.1523/JNEUROSCI.3135-20.2021. Epub 2021 Jul 9.J Neurosci. 2021.PMID:34244365Free PMC article.
- Altered surface trafficking of presynaptic cannabinoid type 1 receptor in and out synaptic terminals parallels receptor desensitization.Mikasova L, Groc L, Choquet D, Manzoni OJ.Mikasova L, et al.Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18596-601. doi: 10.1073/pnas.0805959105. Epub 2008 Nov 17.Proc Natl Acad Sci U S A. 2008.PMID:19015531Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous